Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
Eli Lilly and Co.
, the maker of
Zepbound
and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for diabetes and
weight loss
.
The trial of the drug, orforglipron, measured its efficacy and safety in adults with Type 2 diabetes compared to a placebo. It found the pill lowered A1C, a blood level used to diagnose diabetes, by an average of 1.3% to 1.6%, across different doses, after 40 weeks.
Participants taking the highest dose also lost an average of 16 pounds.
"Given that participants had not yet reached a weight plateau at the time the study ended, it appears that full weight reduction was not yet attained," the company said in a news release. It did not include information on the demographics of the people who participated in the trial.
The most commonly reported adverse effects were mild to moderate gastrointestinal issues, including diarrhea, nausea, indigestion, constipation and vomiting.
The pill, which would offer an alternative to injections, is the first small molecule oral GLP-1 to succeed in a Phase 3 trial, the company said.
Eli Lilly says it plans to submit orforglipron to the U.S. Food and Drug Administration for approval as a Type 2 diabetes treatment in 2026. For weight management, it plans to submit the drug to global regulatory agencies by the end of this year.
"If approved, the company is confident in its ability to launch orforglipron worldwide without supply constraints," the news release said. "This would further Lilly's mission to reduce chronic diseases like type 2 diabetes, which is expected to impact an estimated 760 million adults by 2050."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined with GLP-1 therapies to prevent post-treatment weight rebound. NEW TAIPEI CITY, June 10, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) announced today its participation in the 2025 BIO International Convention, to be held from June 16 to 19 in Boston, U.S.A. Caliway's Vice President, April Yuan, will deliver an oral presentation on June 17, highlighting the company's latest progress in R&D and pipeline development. The presentation will cover recent updates on CBL-514, first-in-class injectable drug candidate for large-area, site-specific fat reduction, including its development across multiple indications—subcutaneous fat reduction, cellulite, and Dercum's disease. For the first time at an international conference, Caliway will also share preclinical data on a potential new indication: weight rebound management through a combination therapy with GLP-1 receptor agonists. As GLP-1 receptor agonists gain widespread use globally, post-discontinuation weight rebound has become a significant, yet unmet clinical concern. According to published studies, only 10% of patients are able to maintain weight loss after stopping GLP-1 treatment. Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy. CBL-514 works by directly targeting the root cause—subcutaneous fat—through selective induction of adipocyte apoptosis. It may serve as a complementary combination therapy to GLP-1s, pairing systemic weight loss with precise body contouring. Caliway plans to submit a Phase 2 IND application to the U.S. FDA for this new indication in Q4 2025. "We believe post-weight-loss weight rebound is a promising unmet market need," said Vivian Ling, CEO of Caliway. "CBL-514 has the potential to serve as a complementary combination therapy with GLP-1 treatments — with GLP-1s driving weight reduction, and CBL-514 reshaping and maintaining outcomes through localized fat reduction, enhancing the overall treatment impact and long-term value." The BIO International Convention is the world's largest and most influential biotechnology event, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment. Caliway Presentation at BIO 2025: Date & Time: Tuesday, June 17, 2025 | 11:45 AM – 12:00 PM (EDT) Location: Room 154 | Boston Convention & Exhibition Center Speaker: April Yuan, VP, Caliway Biopharmaceuticals Session Info: About CBL-514CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas without causing any systemic side effects on the central nervous system, cardiovascular system, and respiratory system. As of May 2025, 10 clinical trials with a total of 520 subjects have been completed with all efficacy and safety endpoints met. Caliway is currently investigating multiple indications for CBL-514, including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. CBL-514D, the same active pharmaceutical ingredients (APIs) but under different formulation, is being studied for additional indications such as Dercum's disease and more. About Caliway BiopharmaceuticalsCaliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Exchange (TWSE-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: DisclaimerThis article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change. View original content to download multimedia: SOURCE Caliway Biopharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Heungkong, Panasonic and Tantron Unveil Breakthrough in Forest-Ecology-Inspired Indoor Bionic Technology
GUANGZHOU, China, June 10, 2025 /PRNewswire/ -- Heungkong Group, Panasonic Electric, and Tantron Technology have announced the mid-stage outcomes of their collaborative innovation, the "8 Constants+ Forest Environment System," on World Environment Day, June 5, 2025. This pioneering solution signifies a significant advancement at the intersection of smart environmental control, ecological science, and human well-being, setting a new benchmark for sustainable development. As the world's first intelligent indoor regulation system modeled on forest ecosystem dynamics, the 8 Constants + Forest Environment System applies the principles of environmental bionics to recreate a forest-like indoor environment. The system operates through eight core elements: constant temperature, humidity, oxygen level, cleanliness, quietness, airflow, intelligence, and control. Former Japanese Prime Minister Yukio Hatoyama and former European Council President and ex-Prime Minister of Sweden, John Fredrik Reinfeldt, delivered congratulatory video messages for the occasion. Mr. Hatoyama said, "Environmental challenges have become a critical global issue and we are making every effort to address it. This collaboration harnesses the technical strengths of China and Japan to create a new-generation atmospheric platform—a powerful example of bilateral innovation. We are confident that this advancement will support smarter, healthier, and more comfortable living environments for people in the two countries and beyond." Mr. Reinfeldt commended the milestone, stating that healthy indoor environments are a global priority and that the system sets an exemplary standard for indoor environmental enhancement worldwide. Experts in green technology, environmental systems, and health-focused architecture also commended the platform for its technical achievements. All-China Environment Federation chairman Wang Xiufeng commented, "The 8 Constants + Forest Environment System provides an intelligent ecological solution to address human health challenges. It demonstrates how advanced technologies can drive the shift toward sustainable living, while reinforcing the role of enterprises in promoting ecological stewardship and global climate action." Xing Lei, Secretary-General of the World Green Design Organization, added that the system delivers a novel model for sustainable and healthy living spaces. Heungkong Group chairwoman Mei Hing Chak said, "Technological innovation is the engine of our business strategy. By working closely with world-class scientific institutions and industrial partners, Heungkong has merged Panasonic's global leadership in environmental sensing, Tantron's proprietary algorithmic intelligence, and the practical ecosystem of our Heungkong-1 flagship residential project. The result is a new standard for indoor environmental science. In the years ahead, we will expand our innovation framework and deepen international partnerships to accelerate deployment and scalable impact." Matsui Jun, Head of Panasonic China & Northeast Asia's HVAC Division, described the joint project as a testament to China-Japan technical synergy, "This system will set new industry benchmarks for healthy living environments, delivering tangible benefits to communities and consumers." Tantron founder Yao Minghai noted, "The 8 Constants + Forest Environment System delivers multiple world-first innovations, most notably its self-learning natural language interface. Unlike conventional systems requiring precise commands, the system, for instance, interprets casual expressions like 'I'm sleepy' to automatically dim lights, adjust ambiance and optimize sleep temperature. This isn't just automation - it's an adaptive living system that anticipates needs and personalizes experiences." The '8 Constants+ Forest Environment System' brings together the core strengths of all three partners in a strategic collaboration: Panasonic provides the hardware platform, integrating its industry-leading precision sensors and HVAC technologies; Tantron drives innovation through proprietary AI algorithms and adaptive interaction architecture; and Heungkong Group leads scenario-based application and market enablement, drawing on its real-world project expertise to ensure scalable, ready-for-deployment solutions. View original content to download multimedia: SOURCE Heungkong Group
Yahoo
6 hours ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
